Drug intelligence / Profile preview

MT207

Development stage: Preclinical
Lead developer: T-MAXIMUM Biopharmaceuticals
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

MT207 is a CRISPR-based universal CAR-T cell therapy being developed by T-MAXIMUM Biotech for the treatment of solid tumors, including high-grade gliomas. GenScript provides cGMP-grade CRISPR sgRNA reagents to support its development and commercialization, with the goal of accelerating regulatory approvals in China and the US.

Targets

B7-H3

Beyond the preview

Go deeper on MT207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT207.

Explore the full profile